• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    FDA Contamination Warning Could Be A Game Changer For Jabil’s (JBL) Pharma Ambitions

    Simply Wall St·09/04/2026 08:31:06
    Listen to the news
    • In September 2026, the U.S. Food and Drug Administration issued a warning letter to Jabil’s Pharmaceutics International Inc. facility, citing multiple significant violations of Current Good Manufacturing Practice for sterile injectable drugs, including inadequate investigations into fungal contamination and weak quality oversight.
    • The FDA’s findings point to systemic quality-control and documentation weaknesses in Jabil’s pharmaceutical operations, raising material questions about its ability to reliably manufacture sterile products within this regulated market.
    • We’ll now examine how the FDA’s warning on systemic fungal contamination risks could affect Jabil’s earlier investment narrative around pharmaceutical expansion.

    The latest GPUs need a type of rare earth metal called Dysprosium and there are only 30 companies in the world exploring or producing it. Find the list for free.

    Jabil Investment Narrative Recap

    To own Jabil, you need to believe its core manufacturing and AI infrastructure businesses can offset volatility in more specialized areas like pharmaceuticals. The FDA warning letter against Pharmaceutics International introduces a fresh, company specific compliance risk and could weigh on the near term pharma expansion catalyst if remediation proves costly or slow, even if the broader AI and industrial stories remain intact.

    Among recent announcements, Jabil’s US$35 billion full year 2026 revenue guidance stands out, as it implicitly incorporates contributions from Regulated Industries, including health care and pharma. The FDA’s findings around systemic quality issues at Pharmaceutics International may prompt investors to question how resilient that portion of the growth plan is versus Jabil’s other drivers, such as AI infrastructure and India manufacturing expansion.

    Yet beneath Jabil’s AI and India growth story, investors should be aware of how unresolved FDA findings could ripple through...

    Read the full narrative on Jabil (it's free!)

    Jabil's narrative projects $53.9 billion revenue and $2.0 billion earnings by 2029. This requires 17.0% yearly revenue growth and a $1.1 billion earnings increase from $862.0 million today.

    Uncover how Jabil's forecasts yield a $441.44 fair value, a 44% upside to its current price.

    Exploring Other Perspectives

    JBL 1-Year Stock Price Chart
    JBL 1-Year Stock Price Chart

    Some of the lowest analysts were already cautious, assuming Jabil reaches about US$48.9 billion in revenue and US$2.0 billion in earnings by 2029, and this FDA warning could reinforce their concern that concentrated pharma and AI exposures might prove more fragile than the consensus expects.

    Explore 3 other fair value estimates on Jabil - why the stock might be worth as much as 68% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Jabil research is our analysis highlighting 4 key rewards and 1 important warning sign that could impact your investment decision.
    • Our free Jabil research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Jabil's overall financial health at a glance.

    Contemplating Other Strategies?

    Our daily scans reveal stocks with breakout potential. Don't miss this chance:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.